Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis found.
from USATODAY - News Top Stories https://ift.tt/2x7yhr2
0 comments:
Post a Comment